Etretinate therapy for generalized pustular psoriasis in children

Shelnitz, L. S.

doi:10.1001/archderm.123.2.230

Cited by 18 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the uncommon nature of these types of psoriasis, there are few reports of treating childhood psoriasis with MTX (9), and oral retinoids generally are administered (10)(11)(12). However, the major limitations of oral retinoids are cost and availability.…”

Section: Discussionmentioning

confidence: 99%

Methotrexate in Childhood Psoriasis

Kumar

Dhar

Handa

et al. 1994

Pediatric Dermatology

View full text Add to dashboard Cite

We treated childhood psoriasis with methotrexate (MTX) in seven children (4 boys, 3 girls) over 7.5 years. Their ages and duration of disease varied from 3.5 to 16 years (mean 12.14 yrs) and 4.8 months to 5 years (mean 2.2 yrs), respectively. Psoriatic erythroderma was seen in three patients, generalized pustular psoriasis in two, recalcitrant psoriasis and psoriatic arthropathy in one each. Pre-MTX liver biopsy performed in 4 children showed grade I changes. Methotrexate was given in a single weekly oral dose of 3.75 to 25 mg (mean 16.6 mg). The duration of treatment necessary to control the disease varied from 6 to 10 weeks (mean 7.9 wks). Total duration of MTX therapy was 31.2 to 46.4 weeks (mean 38.8 wks). Posttherapy disease-free interval ranged between 14.4 and 16.8 weeks (mean 15.5 wks). Follow-up after withdrawal of MTX was 16 to 28 weeks (mean 22.3 wks). Total cumulative MTX dose ranged from 390 to 960 mg (mean 683.6 mg). Side effects were nausea and vomiting in three patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Methotrexate in Childhood Psoriasis

Kumar

Dhar

Handa

et al. 1994

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…Low-dose methotrexate has been used with success in the pediatric setting 105 . Success with systemic retinoids has also been reported, but must be used with care in the pediatric population 142, 143 .…”

Section: Pustular Psoriasis and Clinical Variantsmentioning

confidence: 99%

Autoinflammatory Pustular Neutrophilic Diseases

Naik

Cowen

2013

Dermatologic Clinics

114

View full text Add to dashboard Cite

SYNOPSIS The inflammatory pustular dermatoses constitute a spectrum of non-infectious conditions ranging from localized involvement to generalized disease with associated acute systemic inflammation and multi-organ involvement. Despite the variability in extent and severity of cutaneous presentation, each of these diseases is characterized by non-infectious neutrophilic intra-epidermal microabscesses. Many share systemic findings including fever, elevated inflammatory markers, inflammatory bowel disease and/or osteoarticular involvement, suggesting potential common pathogenic links (Figure 1). The recent discoveries of several genes responsible for heritable pustular diseases have revealed a distinct link between pustular skin disease and regulation of innate immunity. These genetic advances have led to a deeper exploration of common pathways in pustular skin disease and offer the potential for a new era of biologic therapy which targets these shared pathways. This chapter provides a new categorization of inflammatory pustular dermatoses in the context of recent genetic and biologic insights. We will discuss recently-described monogenic diseases with pustular phenotypes, including deficiency of IL-1 receptor antagonist (DIRA), deficiency of the IL-36 receptor antagonist (DITRA), CARD14-associated pustular psoriasis (CAMPS), and pyogenic arthritis, pyoderma gangrenosum, acne (PAPA). We will then discuss how these new genetic advancements may inform how we view previously described pustular diseases, including pustular psoriasis and its clinical variants, with a focus on historical classification by clinical phenotype.

show abstract

“…Methotrexate, retinoids and cyclosporine have all been used in children for arthropathic, erythrodermic or pustular psoriasis. [18][19][20][21] With retinoids there is a concern about premature epiphyseal closure in children. 22 The safety of methotrexate in children has not been established, although it has been used in a number of dermatological conditions.…”

Section: Psoriasis In Childrenmentioning

confidence: 99%